Objective To assess if pregnancies among women with Addison's disease (AD) are at higher risk of adverse maternal and neonatal outcomes.
Introduction
Chronic primary adrenal insufficiency, also referred to as Addison's disease, is a rare and potentially life-threatening disorder whose prevalence is believed to be increasing. 1 Most recent data report disease prevalence as high as 144 per 1 million people, although this is believed to be an underestimate. 2 Women are more frequently affected than men, and diagnosis peaks in the third and fourth decades of life, during a woman's reproductive years. 3 Addison's disease is characterised by the destruction and atrophy of the adrenal cortex. Subsequent adrenal insensitivity to adrenocorticotropic hormone and angiotensin II results in impaired secretion and variable deficiencies of cortisol, aldosterone and androgens. Before the introduction of steroid therapy in the 1950s, Addison's disease was uniformly fatal. Today, it is a treatable chronic condition whose treatment includes standard replacement therapy with hydrocortisone for cortisol replacement and fludrocortisone for aldosterone replacement, and second, emergency therapy during an adrenal crisis or stress to the body. 4, 5 However, even if well controlled with adequate hormonal substitution, without the ability to mount an appropriate stress response through cortisol secretion, a life-threatening state of shock known as Addison's crisis may ensue in any stressful situation.
Given the rarity of Addison's disease in the general population, and therefore even lower prevalence in the pregnant population, limited and contradictory data exist on maternal and neonatal outcomes in pregnancies complicated by Addison's disease. [6] [7] [8] [9] The vast majority of the literature comprises observational findings from case reports, and more recently one larger population-based study. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The objective of the present study was to assess, at the population-level, if there was an association between Addison's disease in pregnancy and adverse maternal or neonatal outcomes.
Methods

Data source
We conducted a retrospective population-based cohort study on all births registered in the Healthcare Cost and Utilization Project-Nationwide Inpatient Sample (HCUP-NIS) over a 9-year period from 2003 to 2011, inclusive. HCUP-NIS is a publicly available US inpatient healthcare multi-state database, containing information on more than 7 million hospital stays per year. Both clinical and nonclinical information pertaining to patients is recorded in their hospital discharge abstract. Data are recorded in the database according to the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) classification.
Study population
We first extracted all records with a delivery-related discharge diagnosis or birth-related procedural diagnosis using ICD-9 codes (ICD-9 diagnosis codes 650x, 677x, 651x-676x, excluding 63x and procedure codes 72x, 73x, 740x, 741x, 742x, 744x, 7499x). Women who were pregnant and died during admission were also identified (ICD-9 code 761.6 and NIS code Died). Including only women with delivery-related or birth-related diagnoses ensured that all participants were only included once, even if they had multiple admissions during their pregnancies. Next, among these women, we identified those who had a diagnosis of corticoadrenal insufficiency. These women comprised the 'exposed' group. All the remaining participants, who also delivered during their admission but did not have corticoadrenal insufficiency, comprised the comparison group. It should be noted that as the HCUP-NIS database does not allow us to follow the same individual over time, we were not able to determine if a given woman had multiple pregnancies during our study period. Any correlation that may exist, in our opinion, would be minor as the study population is exceedingly large but the possible clustering effect on study results should be noted. Additionally, the database does not provide information regarding any medications taken during pregnancy, including hormonal replacement therapy.
There is no specific ICD-9 code for Addison's disease. As patients with Addison's disease are deficient in all hormones produced by the adrenal cortex, including both glucocorticoids and mineralocorticoids, we considered the diagnosis of corticoadrenal insufficiency (255.4) as an adequate proxy for a diagnosis of Addison's disease. This approach was in keeping with other groups, who have used the same code to identify patients with Addison's disease. 10, 22 Note, as exposure status was identified using codes for corticoadrenal insufficiency, rather than Addison's disease, we believe that the results of this study would also be applicable to women with secondary corticoadrenal insufficiency.
Statistical analysis
Maternal outcomes were identified using appropriate ICD-9 diagnosis and procedure codes and were categorised into three groups: antepartum, intrapartum and postpartum. Antepartum outcomes measured were: hypertensive disorders of pregnancy (gestational hypertension (642.3), mild and severe pre-eclampsia (642. 4 3), postpartum infection (major puerperal infection including endometritis, fever, cellulitis, peritonitis, pyema, salpingitis, septicaemia, 670), blood transfusions (99.0), maternal death (761.6) and length of stay (less than or greater than 3 days, retrieved from NIS data set).
Venous thromboembolic disease (VTE, including antepartum or postpartum deep venous thrombosis and pulmonary embolism 671.3, 671.4, 673.2), and overall maternal infection (intrapartum generalised infection of the amniotic cavity, generalised infection during labour, and postpartum infection 659.3, 658.4, 670) were considered separately for analysis.
Neonatal outcomes measured were: congenital anomalies (740-757, 759), intrauterine fetal demise (656.4), and small-for-gestational-age (SGA) infant (656.5, 764.0, 764.1). Of note, the codes used to capture births complicated by SGA were selected in consideration of an earlier publication examining the validity of different codes in ICD-9. The authors suggest using code 656.5 for SGA, which would offer high specificity but low sensitivity. In order to capture more births with SGA, we added two additional codes (764.0 and 764.1). 23 In our analysis, we first estimated the overall prevalence of Addison's disease in our study cohort and then calculated the annual prevalence of this disease over the study period. We then compared baseline demographic and clinical characteristics between the two study groups. The chisquare test was used to compare baseline variables between groups. Baseline variables with missing data were excluded from the chi-square analyses presented in Table 1 . Odds ratios (OR) with corresponding 95% confidence intervals (95% CI) were calculated for all maternal and neonatal outcomes using unconditional logistic regression analysis. All models were adjusted for baseline clinical and demographic characteristics described in Table 1 . Organising maternal outcome variables chronologically as being relevant to the antepartum, intrapartum or postpartum periods allowed us to appropriately adjust for variables that may potentially confound downstream relationships, allowing us to estimate the unconfounded independent effects of Addison's disease on maternal outcomes in each period. Hence, in addition to baseline characteristics, analyses of intrapartum outcomes were also adjusted for antepartum variables, and postpartum outcomes were also adjusted for both antepartum and intrapartum variables. Outcomes not classified to a specific time period (VTE and maternal infection) and neonatal outcomes were adjusted for baseline maternal characteristics only. As missing data were rare for the outcomes variables, women with missing data and those who did not experience the specific outcome of interest were grouped together.
All analyses were performed with statistical software package SAS ENTERPRISE GUIDE 6.1 (Cary, NC, USA). This study used exclusively publicly available data; therefore, according to the Tri-Council Policy statement (2010), institutional review board approval was not required.
Results
Between 2003 and 2011, 7 772 999 pregnant women delivered or died, of which 552 had Addison's disease and 7 772 447 did not have a code for corticoadrenal insufficiency. The overall population prevalence of Addison's disease during the study period was 5.5 per 100 000. As shown in Figure 1 , the prevalence of Addison's disease in pregnancy steadily increased from 5.6 per 100 000 in 2003 to 9.6 per 100 000 in 2011.
Baseline clinical and demographic characteristics between the two cohorts are shown in Table 1 . Compared with the non-Addison's group, women with Addison's disease were significantly more likely to be older, Caucasian, belonging to a higher income quartile, be covered by private insurance or Medicare, and be treated in an urban teaching centre. Importantly, the Addison's group was significantly more likely to have pre-existing hypertension, diabetes mellitus, or thyroid disease. There were no significant differences in body mass index, history of previous caesarean section or smoking. 
Discussion
Main findings
We identified that pregnant women with Addison's disease are at higher risk for the following adverse outcomes: maternal mortality, preterm delivery, PPROM, caesarean section, impaired wound healing, maternal infections, venous thromboembolic disease, requiring transfusions, prolonged hospital admissions, as well as SGA babies and congenital anomalies.
Strengths and limitations
Study limitations are related primarily to using data not specifically collected for our study, as well as the retrospective study design. First, there is no specific ICD-9 code for Addison's disease. However, as mentioned above, since Addison's disease by definition refers to patients with corticoadrenal insufficiency and other authors have used the same code in their studies, we consider our identification of patients presumed to have Addison's disease to be valid. Additionally, important clinical information including medications (type or dosage), disease duration and severity, and cause of maternal death, are not available in the HCUP-NIS database. Knowledge of such variables would have allowed further interpretation of our results. We also acknowledge that there always exists the possibility of misclassification of diagnosis and outcome variables. However, since maternal and neonatal outcomes are variables commonly measured in all pregnancies, we assume misclassification would be minimised, and if anything, would be nondifferential in nature, resulting in skewing of results towards the null. Lastly, although the observed increased prevalence of Addison's disease during the study period may be due in part to differences in coding practices over time, it is in agreement with the observed increasing prevalence seen in the general population.
Our study has notable strengths. First, the retrospective population-based cohort design among patients in the USA allowed us to identify over 7.7 million births and 552 pregnancies with Addison's, a rare disease. Additionally, our results should be generalisable to women with Addison's disease in developed countries where adequate treatment is available. Further, we had significant power to detect adverse pregnancy outcomes and adequately adjust analyses for potential confounders, allowing us to better estimate the true effect of Addison's disease on antepartum, intrapartum and postpartum outcomes (although small numbers may have hampered some analyses). Given the significance of Addison's disease and its impact on obstetric care, we believe the majority of women with Addison's were appropriately identified as cases. Also, data quality is considered to be high, as the HCUP organisation has extensive data quality control measures in place (although we acknowledge that the frequency of obesity and morbid obesity appear to be underestimated in our study, as was smoking history). 24 
Interpretation
We identified that impaired fetal growth and congenital anomalies were more common in women with Addison's disease. Case reports have either found fetal growth to be normal or to be restricted in women with Addison's disease. 10, [25] [26] [27] [28] [29] [30] The main Addison's treatments, hydrocortisone and fludrocortisone, are both classified as drug category C by the Food and Drugs Administration, meaning benefits probably outweigh the risks of teratogenicity. Some existing data show an association between corticosteroids and oral NS, not statistically significant; PPROM, premature preterm rupture of membranes. *All models adjusted for demographic and clinical variables listed in Table 1 . In addition, intrapartum outcomes are also adjusted for antepartum outcomes and postpartum outcomes are adjusted for both antepartum and intrapartum outcomes. clefts, whereas others show no teratogenic potential, and evidence is conflicting as to whether they cause decreased birthweight. [31] [32] [33] [34] Due to the limitations of our data source, we are unable to elaborate on the specific nature of the congenital anomalies or comment on the possible association between steroid therapy and the occurrence of congenital anomalies or impaired fetal growth.
In agreement with previous case studies and one population-based study, we found women with Addison's disease had a greater risk of preterm birth. 10, 26, 27, 30 It is hypothesised that the hypothalamic-pituitary-adrenal (HPA) axis plays an important role in the timing of parturition, and that corticotropin-releasing hormone levels may serve as a 'placental clock'. 1, 11, 35 Therefore, dysfunction of the HPA axis in Addison's disease contributes to the increased risk of preterm delivery.
Addison's patients had a significantly increased risk of maternal infections and postpartum wound complications. Acute wound healing is a complex process, where the early inflammatory phase ultimately leads to the repair and restoration of cellular function. 36, 37 The immunosuppressive properties of systemic glucocorticoid therapy blunt this inflammatory response, inhibiting subsequent wound repair, and increase the risk of infection in a dose-and duration-dependent manner. Furthermore, glucocorticoids blunt the classic clinical features of infection. 38, 39 We hypothesise that the supra-physiological stress doses of glucocorticoids likely given in the intrapartum and early postpartum periods, through the aforementioned mechanisms, contribute to impaired wound healing and increased risk of maternal infection. Treating physicians should anticipate infections in these patients with both usual and unusual organisms, monitor for subtle signs and symptoms of infection, and may consider antibiotic prophylaxis.
In addition to baseline increased VTE risk surrounding pregnancy, women with Addison's disease have additional risk factors for VTE. First, they are more likely to deliver by caesarean, develop infections, and have prolonged hospital admissions (which impede mobility). Second, autoimmune disorders may be considered hypercoagulable states, 40 of relevance in our study population as autoimmune destruction of the glands is responsible for 70-90% of cases of Addison's disease in developed countries. 41, 42 Other population-based studies have also found that women with Addison's are at increased risk of developing VTE. 22, 43 Third, the treatment of Addison's disease may contribute to the risk of VTE, as corticosteroids may affect the coagulation system and promote thrombosis. 44 Therefore, we suggest considering postpartum thromboprophylaxis.
In agreement with existing literature, we found that women with Addison's were more likely to deliver by caesarean section. 10 Guidelines for obstetrical management of patients with Addison's disease do not suggest or recommend that an elective cesarean section is safer than a vaginal delivery. 6, 11, 12, 17 Despite this, some caesarean sections may have been elective, hoping to have more control over their delivery and avoid potential Addisonian crises during natural labour and delivery. 10 Since these patients are more susceptible to infections, impaired wound healing and VTE, we propose that in the absence of standard contraindications, a vaginal delivery should be encouraged.
Before the advent of corticosteroid treatment of Addison's disease, maternal mortality as high as 35% was reported. 45, 46 Maternal mortality declined in the 1940s when adrenal cortical extracts became available, and decreased further with the introduction of synthetic steroids. In our study, the maternal mortality rate among women with Addison's disease was 0.5%. After searching the published literature we did not identify any cases of maternal death attributable to Addison's disease since the 1950s. 12 Given that Addison's disease is often difficult to diagnose, and a possible bias in the literature toward publishing successful pregnancies, we believe maternal mortality may be underreported. Although we cannot ascertain the causes of death, we feel that it is important to draw attention to the maternal deaths in our cohort and emphasise that Addison's disease can become life-threatening in stressful circumstances.
Conclusion
Addison's disease is a risk factor for adverse maternal and neonatal outcomes. This study provides strong evidence to recommend that these patients should be referred to tertiary care centres for antepartum care by a multidisciplinary team who can adequately counsel and closely monitor these patients during the intrapartum and postpartum periods.
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